Background: Dose-dense (dd) regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The German Adjuvant Intergroup Node-positive trial aimed at optimizing intense dd (idd) strategies by evaluating drug combinations and the addition of capecitabine.
Introduction
Dose-dense (dd) [1, 2] , intense dd (idd) [3, 4] and tailored dd regimens [5] with granulocyte colony stimulating factor support demonstrated higher efficacy in high-risk breast cancer (BC) patients compared with conventionally scheduled chemotherapy. Particularly the idd epirubicin (E), paclitaxel (P), cyclophosphamide (C) regimen (iddEPC-regimen) reveals an impressive superior overall survival (OS) benefit in patients with !4 positive lymph nodes [3, 4] , compared with conventional (q3w) EC followed by 3-weekly paclitaxel. Based on this data, we consider iddEPC as a standard regimen in patients with high risk of recurrence. In contrast BC patients with a low risk profile did not benefit from dd regimens due to their general better prognosis [6, 7] .
Since the incorporation of taxanes into the adjuvant therapy of BC, no new cytotoxic agents have added additional benefit to established dd or standard anthracycline/taxane containing regimens [6, 8] . When the German Adjuvant Intergroup Node-positive (GAIN) trial was designed, a randomized phase III trial demonstrated a survival benefit for the combination of docetaxel/capecitabine in patients with anthracycline-pretreated metastatic disease [9] . A synergistic effect of the simultaneous application of paclitaxel and capecitabine was expected based on the preclinically observed taxane-mediated up-regulation of thymidine phosphorylase in tumor cells, which increases the transformation of capecitabine into its active form, 5-fluorouracil [10] . In order to further improve the iddEPC regimen, we have incorporated capecitabine into the experimental arm (ddEC-PwX). Moreover, the 2 Â 2 factorial design of the GAIN trial explored the efficacy of oral ibandronate versus observation as additional strategy to improve outcome [11] .
Patients and methods

Selection of patients and treatment
Details of the trial were extensively published [11] . In brief, inclusion criteria were female patients suitable for idd chemotherapy (!18 years of age and biologically younger than 65 years) with histologically confirmed primary node-positive BC; histological complete resection of the primary tumor and !10 resected axillary nodes; no evidence of distant metastasis (negative chest X-ray, abdominal ultrasound, bone scan). Patients were excluded in the case of inadequate organ function, chronic infections or secondary malignancy. All patients provided written informed consent.
Patients were randomized within 2-12 weeks of definitive axillary dissection. All patients received primary prophylaxis of anemia with either epoetin beta 30 000 IU weekly or darbepoetin alfa 4.5 mg/kg q2w prescribed equally at each center, together with oral supplementation of 200 mg Fe 2þ per day in order to avoid a decline of Hb below 12 g/dl. The treatment was stopped when hemoglobin levels reached >14 g/dl. Chemotherapy consisted of three courses of epirubicin 150 mg/m 2 followed by three courses of paclitaxel 225 mg/m 2 followed by three courses of cyclophosphamide 2500 mg/m 2 (reduced to 2000 mg/m 2 after recruitment of approximately 1200 patients), all given at 2-week intervals (iddEPC) or epirubicin 112.5 mg/m 2 and cyclophosphamide 600 mg/m 2 for four 2-week courses followed by 10 weekly courses of paclitaxel 67. Table S1 , available at Annals of Oncology online). Patients treated with iddEPC and ddEC received primary prophylaxis with pegfilgrastim given subcutaneously on day 2 of each cycle. After amendment 3 (August 2007) all patients in the iddEPC arm were further randomized to receive pegfilgrastim on day 2 versus 4 [12] . HER2-positive patients received 1 year of adjuvant trastuzumab (starting May 2006) given simultaneously with iddP or PwX. Radiotherapy and endocrine treatment were applied according to 'Arbeitsgemeinschaft für Gyn€ akologische Onkologie' (AGO) guidelines [13] .
Objectives
Primary objective was disease-free survival (DFS), defined as time from randomization to any local, regional or distant recurrence or death from any cause after adjuvant treatment with either iddEPC or ddEC-PwX. Secondary objectives were OS, safety, compliance and DFS in subgroups of hormone receptor (HR) positive or negative disease and in groups with 1-3, 4-9 or >10 involved nodes.
Study investigations
Clinical history and concomitant medications as well as physical examinations were recorded every 3 months during the first 3 years and thereafter every 6 months. Breast imaging had to be carried out annually. All other investigations were recommended if clinically indicated.
Statistics
The GAIN study was an open label, prospectively randomized phase III trial using a 2Â2 factorial design. The futility analysis for chemotherapy was carried out at the same time as for ibandronate question, but the futility boundary was not crossed. The error rate for false positive outcome was set to two-sided a ¼ 0.05. To test simultaneously two primary objectives, the corrected value of a ¼ 0.0361 for highly correlated endpoints was used [14] . It was expected that there would be an absolute improvement in 5-year DFS from 75% to 79% for patients receiving ddEC-PwX. To compare the arms using a two-sided a ¼ 0.0361 and 1 À b ¼ 0.8, 801 events needed to be observed. Assuming a common exponential drop-out rate of 5%, and an overall study period of 96 months and planning for one interim efficacy analysis for both primary objectives with adjusted a1 ¼ 1%, two sided, after 50% of the expected events, the total number of patients was chosen equal to 3.000 (i.e. 1500 patients per arm) [15] .
Patients eligibility was centrally confirmed and dynamic allocation using the minimization method of Pocock and Simon [14] was used to randomize the patients. The minimization factors were center, nodal status (pN1, pN2 or pN3) and HR status.
The event rate was lower than originally assumed and it would have taken additional 2.5-3 years of follow-up to observe the initially planned number of events. The protocol board therefore decided in agreement with the study IDMC to perform the final analysis of the primary objective A in a time-driven rather than event-driven fashion (i.e. 5 years after recruitment of the last patient and not after 801 events).
All efficacy analyses were carried out on an intent-to-treat (ITT) basis in all patients who received at least one (even incomplete) dose of chemotherapy treatment.
For the analysis of safety and compliance patients were included as treated. Treatment groups were compared with two-sided Fisher's exact test which is to be considered purely descriptive. Time-to-event outcome parameters were estimated by the Kaplan-Meier product-limit method, and compared between treatment groups using the log-rank test. Univariate Cox proportional hazards models were used to calculate HRs. A multivariate Cox model was used to adjust for relevant baseline characteristics. A univariate Cox model was carried out in subgroups predefined by stratification factors (HR status and pN status) as well as by post hoc defined baseline factors in statistical analysis plan. Cox models including interaction between subgroup factors and therapy were used to test for heterogeneity across subgroups. All statistical tests were twosided; the significance level, except for the primary objective, was set to 0.05 and was unadjusted for multiple comparisons. The protocol was reviewed by all responsible local ethics committees. Conduct of the trial was supervised by an IDMC. None of the supporting companies had any role in the study design, data collection, data analysis, data interpretation, or writing of the report. Baseline characteristics were comparable between both arms (Table 1) . Median age at diagnosis was 50 years (range 20-71 years). In both arms, the median number of involved axillary nodes was five (range 1-53).
Results
Patient characteristics
Treatment
All planned cycles of chemotherapy were administered to 91.7% of patients receiving iddEPC and to 89.1% of patients receiving ddEC-PwX (14.3% completed paclitaxel but discontinued capecitabine). Consistently, we observed a dose reduction in 23.0% of patients in the iddEPC arm and 37.1% of patients in the ddEC-PwX arm. Relative total dose intensity (RTDI) was !85% in 82.7% of all patients (85.2% with iddEPC, 79.7% with ddECPwX). We observed significantly more therapy related deaths with ddEC-PwX compared with iddEPC (11 versus 3; P ¼ 0.034). All three patients in the iddEPC arm died as a consequence of septic organ failure and had received a cyclophosphamide dose of 2500 mg/m 2 . Three patients in the ddEC-PwX arm suffered a sudden death (cardiac failure, pulmonary embolism), seven died from septic organ failure and one from liver failure. Therefore, two amendments were implemented: (i) reduction of the cyclophosphamide dose from 2500 to 2000 mg/m 2 and antibiotic prophylaxis (oral ciprofloxacin days 5-10 during cyclophosphamide in both arms). No further deaths were observed after dose reduction; (ii) reduction of the dexamethasone dose from 8 to 4 mg weekly in patients receiving PwX. After reduction the incidence of pneumonia grade 3/4 decreased from 3.8% to 2.4% (P ¼ 0.150), but no influence on the incidence of therapy-related death (4 [0.8%] before and 7 [0.7%] after) was observed.
Hematologic toxicity
Significantly more patients experienced grade 3/4 hematologic toxicity [77.0% versus 53.6% (P < 0.001)] and febrile neutropenia (12.0% versus 5.0%, P < 0.001) with iddEPC ( Table 2 ). The reduction of the cyclophosphamide dose significantly reduced the incidence of hematologic toxicity grade 3/4 (supplementary Table S2 , available at Annals of Oncology online). So far, ten (0.3%) secondary hematological malignancies have been reported, equally distributed between both arms.
Nonhematologic toxicity
Major differences in nonhematologic toxicity grade 3/4 were observed between arms (supplementary Table S3 , available at Annals of Oncology online). More thromboembolic events grade 3/4 occurred in the ddEC-PwX arm (8% versus 4.8%; P < 0.001). At the time of occurrence no major differences in the median hemoglobin value were observed (11.5 versus 11.8 g%).
Efficacy
After a median follow-up of 74 months (range 0-114), 645 events and 383 deaths were recorded. There was no statistical significant difference between the two arms with respect to DFS and OS events or estimated 5 year DFS and OS. Five-year DFS rates for ddEC-PwX and iddEPC were 81.7% (95% CI 79.5-83.6%) versus Figure 2 . CONSORT trial flow diagram. C, cyclophosphamide; dd, dose-dense; E, epirubicin; idd, intense dose-dense; ITT, intention to treat; mITT; modified intention to treat; P, paclitaxel; w, weekly; X, capecitabine.
80.2% (95% CI 78.0-82.2%), HR 0.95 (95% CI 0.81-1.11; logrank P ¼ 0.49) ( Figure 3A) . Five-year OS rates according to the Kaplan-Meier estimation were 89.4% for ddEC-PwX (95% CI 87.7%-91.0%) and 89% for iddEPC (95% CI 87.2%-90.6%), HR 0.85 (95% CI 0.69-1.04, log-rank P ¼ 0.10) ( Figure 3B ). RTDI !85% was associated with significantly better DFS compared with RTDI <85% [HR ¼ 0.79 (95% CI 0.64-0.98; log-rank P ¼ 0.028)] (supplementary Figure S1 , available at Annals of Oncology online). In subgroup analyses, this difference was only significant for ER-negative patients. Comparing the influence of an RTDI !85% on DFS between arms, we found a significant advantage only for ddEC-PwX (HR ¼ 0.67; 95% CI 0.51-0.89; logrank P ¼ 0.006) (supplementary Figure S2A and B, available at Annals of Oncology online).
Prognostic and predictive factors
Grade 3 and luminal B-like tumors showed a superior OS with the addition of capecitabine. A trend for improved OS in pre-or perimenopausal patients and in patients not receiving ibandronate was observed (supplementary Figure S3A and B, available at Annals of Oncology online). At multivariable analysis smaller tumor size, lower grade, lower number of positive nodes, HRpositive and ductal invasive carcinoma were associated with superior DFS, whereas a positive HER2 status was associated with worse OS, but had no impact on DFS (supplementary Table S4 , available at Annals of Oncology online).
Discussion
Several studies [1] [2] [3] [4] [5] as well as a pooled analysis of randomized trials [16] demonstrated a higher efficacy of dd compared with conventionally dosed chemotherapy. Consequently, the GAIN trial compared two dd regimens. The addition of capecitabine given simultaneously to weekly paclitaxel did not translate into an increased efficacy in comparison with iddEPC. Valid percent. C, cyclophosphamide; dd, dose-dense; E, epirubicin; ER, estrogen-receptor; idd, intense dose-dense; P, paclitaxel; PgR, progesteron-receptor; w, weekly; X, capecitabine.
The GAIN study also confirmed, that an RTDI !85% is associated with an improved DFS, which seems to be more relevant for patients treated with ddEC-PwX and for the HR-negative group. Treatment related deaths were a major problem mainly with ddEC-PwX, even after reduction of the dose of dexamethasone. The higher incidence of grade 3/4 vascular disorders including thromboembolic events and the higher incidence of respiratory and thoracic disorders may partially explain the elevated treatment related mortality, which obviously contrasts with the significantly lower hematologic toxicity in this arm. The reported rate of secondary leukemia/MDS corresponds to published data from other dd trials [1] .
Regarding the subgroup analysis of OS, patients with G3 and luminal B-like tumors, pre-and perimenopausal patients and patients who had not received ibandronate, showed a superior OS when randomized to ddEC-PwX. This raises the hypothesis that certain subgroups of high-risk patients could benefit from a dd regimen incorporating capecitabine.
In the adjuvant setting, the USON 01062 trial added capecitabine to doxorubicin plus cyclophosphamide/docetaxel and also The statistical significant differences in toxicities between the two arms are written in cursive and highlighted in gray. Within the significant results, the arm with the highest rate of toxicities is highlighted in bold. a Fisher's exact test.
AE, adverse events; ANC, absolute neutrophil count; C, cyclophosphamide; dd, dose-dense; E, epirubicin; idd, intense dose-dense; P, paclitaxel; w, weekly; X, capecitabine; WBC, white blood cells. C, cyclophosphamide; dd, dose-dense; DFS, disease-free survival; E, epirubicin; idd, intense dose-dense; OS, overall survival; P, paclitaxel; w, weekly; X, capecitabine.
failed to meet its primary endpoint of DFS, but a significant advantage for OS was observed [17] . However, these results must be interpreted with caution due to the lower than expected event rate. The Finnish Breast Group compared docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide with the same regimen but simultaneous use of capecitabine with docetaxel and epirubicin/cyclophosphamide. The final analysis showed nonsignificant benefit of capecitabine [18] , whereas a 'meta-analysis' [19] of both studies showed significantly improved survival. The addition of a fourth cytostatic compound (i.e. gemcitabine, 5-fluorouracil) in the NSABP B-38 [6] and the GIM-II trial [2] did not improve efficacy. Controversial results have also been published in the neoadjuvant setting. Whereas the ABCSG-24 trial [20] reported a significantly improved pathologic complete response (pCR) rate after integration of capecitabine into a taxane/anthracycline-based regimen, the addition of capecitabine did not increase pCR rates or OS in the GeparQuattro [21] and NSABP B-40 [22] study. The use of different doses of docetaxel in the control and experimental arms might have lead to a bias in the assessment of capecitabine effect.
In patients with metastatic BC, pyrimidine analogues have been shown to improve outcomes when added to taxanes [9, 23] . However, in the adjuvant setting all trials failed to improve the effectiveness of the established dd regimens by incorporating one of these compounds. The late separation between the iddEPC and ddEC-PwX arms of the Kaplan-Meier curves for OS in our trial may be influenced by the higher incidence of therapy-related deaths in the ddEC-PwX arm, and indicates that a late benefit of capecitabine cannot be excluded and longer follow-up data are warranted.
Dose-dense chemotherapy should be considered one of the preferred options in high-risk BC patients. Trials including 5-fluorouracil or gemcitabine, have shown consistently negative results [2, 6, 8, 22] , independent of whether a dd (q2w) or conventional (q3w) schedule was applied. In contrast, the integration of capecitabine into anthracycline/taxane/cyclophosphamide containing regimens remains a topic of interest and should be further investigated in a meta-analysis.
